Curcumin to Prevent Complications After Elective Abdominal Aortic Aneurysm (AAA) Repair

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

606 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2016-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this program of research is to determine whether curcumin, a natural health product, can prevent acute kidney injury and other complications after elective AAA repair. If proven safe and effective, curcumin is an inexpensive intervention which can be readily applied to almost 50,000 AAA repairs performed worldwide each year. New knowledge about this intervention may also guide its use in other surgical and medical settings to prevent complications to the kidneys, heart and other organs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

NCT01683084

Abdominal Aortic Aneurysm

COMPLETED PHASE4

Intraocular Pressure During Abdominal Aortic Aneurysm (AAA) Repair

NCT00450294

Problem With Vision Blindness Intraocular Pressure Ischemic Optic Neuropathy

COMPLETED

Mechanism and Prevention of Remote Organ Injury Following Ruptured Aortic Aneurysm

NCT00416000

Abdominal Aortic Aneurysm

COMPLETED

Prediction of Abdominal Aortic Aneurysm Shrinkage After Stent-placement With Artificial Intelligence

NCT06250998

AAA - Abdominal Aortic Aneurysm

RECRUITING

Fast Track Management in Elective Open Infrarenal Aortic Aneurysm Repair

NCT00615888

Aortic Aneurysm

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

An abdominal aortic aneurysm (AAA) is a ballooning of the abdominal aorta, the major blood vessel of the body. AAA occurs in up to 2% of adults. Surgeons will plan an AAA repair when the aneurysm grows bigger than 5.5cm, because the AAA might burst without repair. Over 47,000 AAA repairs are performed each year. Despite the benefits of AAA repair there are risks, and the kidneys can be severely injured. We will test whether the natural health product curcumin has an effect on biomarkers of inflammation, kidney injury and heart injury from AAA repair. Curcumin appears to fight oxidation and inflammation, which are ways that the body can be injured by surgery. We will study 600 patients who have elective AAA repair. The patients will receive either curcumin or a matching placebo. We will recruit the 600 patients from 10 centres in Ontario. This study will help us determine whether curcumin exerts any biological effect on biomarkers and whether it is well tolerated. If there is evidence of beneficial effects in this 600 patient trial, this will justify a future larger trial to assess the effects of curcumin on outcomes most important to patients, families and their healthcare providers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury Abdominal Aortic Aneurysm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

curcumin

Patients will take the study medication (500 mg x 4 capsules, twice daily \[BID\]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg., and then another 2000 mg dose 6 hours after the repair. Final dose (2000 mg)is administered morning after repair.

Group Type EXPERIMENTAL

curcumin

Intervention Type DRUG

Patients will take the study medication (500 mg x 4 capsules, twice daily \[BID\]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg and then another 2000 mg dose 6 hours after the repair. Final dose is administered the morning after repair.

placebo

The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

curcumin

Patients will take the study medication (500 mg x 4 capsules, twice daily \[BID\]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg and then another 2000 mg dose 6 hours after the repair. Final dose is administered the morning after repair.

Intervention Type DRUG

placebo

The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NHPID name: curcumin No brand name applicable.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Elective repair of an AAA (excludes thoracic or thoracoabdominal aneurysms)
* 18 years of age or older
* Able to provide informed consent
* Has one or more of the following criteria at time of preoperative assessment:
* x Open repair OR
* x Endovascular repair with ≥ 1 of the following criteria:
* o diabetes mellitus treated with insulin or oral hypoglycemic agents
* o age \> 70 years
* o pre-existing renal impairment (baseline serum creatinine level \>177 μmol/L for men or \>146 μmol/L for women)
* If diabetic, is able and willing to collect and record glucose levels at home

Exclusion Criteria

* emergent or urgent repair (repair \< 3 days from pre-admission visit; ruptured AAA)
* prior renal transplantation
* pregnant or breastfeeding
* active gastrointestinal reflux disease, gastrointestinal ulcers or hepatobiliary disease (including gallstones)
* has active liver disease
* evidence of AKI (\> 50% increase in serum creatinine) in the 30 days prior to repair
* enrolled in another randomized controlled trial
* receipt of ≥ 1 dialysis treatment in the past week
* previous participation in this trial
* repair is scheduled \> 90 days from date of informed consent
* unable to provide written consent
* allergy(ies) to any member of the Zingiberaceae family: turmeric, ginger, curry, cumin, cardamom)
* allergy(ies) to ingredients of the study product or placebo: yellow or red food coloring, gelatin or cellulose
* have a history of major bleeding event in the previous 6 months
* bleeding disorders: a diagnosis of hemophilia, von Willebrand disease, platelets less than 70 for any reason
* history of hypoglycemia in the past 6 months: blood sugar less than or equal to 3.5 mmol/L

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No